Alterations of expression and regulation of transforming growth factor β in human cancer prostate cell lines

• Published in: The Journal of steroid biochemistry and molecular biology 2002-11, Vol.82 (4), p.297-304
• Main Authors: Blanchère, M., Saunier, E., Mestayer, C., Broshuis, M., Mowszowicz, I.
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Blotting, Northern; Culture Media, Conditioned - pharmacology; Dihydrotestosterone - pharmacology; Enzyme-Linked Immunosorbent Assay; Estradiol - pharmacology; Fibroblasts - metabolism; Gene Expression Regulation - drug effects; Gynecology. Andrology. Obstetrics; Hormonal regulation; Humans; Male; Male genital diseases; Medical sciences; Prostate cancer; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; RNA, Messenger - metabolism; Stromal–epithelial interactions; TGFβ; Transforming Growth Factor beta - genetics; Transforming Growth Factor beta - metabolism; Transforming Growth Factor beta1; Transforming Growth Factor beta2; Tumor Cells, Cultured; Tumors
• ISSN: 0960-0760; 1879-1220
• DOI: 10.1016/S0960-0760(02)00218-2

TGFβ can promote and/or suppress prostate tumor growth through multiple and opposing actions. Alterations of its expression, secretion, regulation or of the sensitivity of target cells can lead to a favorable environment for tumor development. To gain a better insight in TGFβ function during cancer progression, we have used different cultured human prostate cells: preneoplastic PNT2 cells, the androgen-dependent LNCaP and the androgen-independent PC3 and DU145 prostate cancer cell lines. We have studied by specific ELISA assays in conditioned media (CM), the secretion of TGFβ1 and TGFβ2 in basal conditions and after hormonal treatment (DHT or E2) and the expression of TGFβ1 mRNA by Northern blot. We have also compared the effect of fibroblast CM on TGFβ secretion by the different cell types. Compared to PNT2 cells, cancer cell lines secrete lower levels of active TGFβ which are not increased in the presence of fibroblast CM. LNCaP cells respond to androgen or estrogen treatment by a 10-fold increase of active TGFβ secretion while PC3 and DU145 are unresponsive. In conclusion, prostate cancer cell lines have lost part of their ability to secrete and activate TGFβ, and to regulate this secretion through stromal–epithelial interactions. Androgen-sensitive cancer cells may compensate this loss by hormonal regulation.